Tuesday , December 12 2017
Home / Managing Editor, Diabetes in Control (page 7)

Managing Editor, Diabetes in Control

Managing Editor, Diabetes in Control

Did You Know: What Are the SGLT-2 Inhibitor Trade-offs?

The overall profile of sodium-glucose cotransporter 2 inhibitors suggests they are a reliable, second-line therapy choice for adults with type 2 diabetes. However, the class is associated with possible side effects that should be carefully considered, according to a Dr. George L. Bakris, MD, director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine at a recent presentation at the Cardiometabolic Health Congress. Dr. Bakris stated that they definitely are preferred second-line agents, absolutely over sulfonylureas, and probably over thiazolidinediones and some other agents as well.

Read More »

A New Paradigm in the Understanding and Treatment of the Metabolic Syndrome: Targeting Alterations within the Biological Clock System

The prevalence of obesity and insulin resistance syndrome, rare only a century ago in most geographic locals of the world are now disorders whose prevalence represents the majority of humans in westernized countries on planet Earth. This simple observation strongly suggests that factors other than or in addition to genetic mutations/alterations are facilitating this rapid onset in disease occurrence world wide. Although the insulin resistance syndrome is viewed by the medical community as a defect of normal physiology, a plethora of available evidence indicates that the insulin resistant condition evolved among vertebrates as a survival strategy to enable increased survivability of ensuing, predictable seasons of low/no food (including glucose) availability.

Read More »